{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T17:12:09Z","timestamp":1785604329006,"version":"3.56.0"},"reference-count":33,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25010","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T22:07:06Z","timestamp":1748556426000},"page":"93-100","source":"Crossref","is-referenced-by-count":1,"title":["The outcome of patients with peripheral T cell lymphoma treated with doxorubicin-based (CHOP) and pirarubicin-based regimen (THP-COP) regimen: a single institution experience"],"prefix":"10.3960","volume":"65","author":[{"given":"Noriyoshi","family":"Iriyama","sequence":"first","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"},{"name":"Department of Hematology and Rheumatology, National Hospital Organization Saitama Hospital, Saitama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Iizuka","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"},{"name":"Division of Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Otake","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hamada","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Koike","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Endo","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Swerdlow SH, Campo E, Harris NL <i>et al.<\/i>"},{"key":"2","unstructured":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, IARC. 2008."},{"key":"3","doi-asserted-by":"crossref","unstructured":"2 Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26: 4124-4130.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"4","doi-asserted-by":"crossref","unstructured":"3 Au WY, Weisenburger DD, Intragumtornchai T <i>et al.<\/i> Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009; 113: 3931-3937.","DOI":"10.1182\/blood-2008-10-185256"},{"key":"5","doi-asserted-by":"crossref","unstructured":"4 Foss FM, Zinzani PL, Vose JM <i>et al.<\/i> Peripheral T-cell lymphoma. Blood. 2011; 117: 6756-6767.","DOI":"10.1182\/blood-2010-05-231548"},{"key":"6","doi-asserted-by":"crossref","unstructured":"5 Armitage JO. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol. 2017; 92: 706-715.","DOI":"10.1002\/ajh.24791"},{"key":"7","doi-asserted-by":"crossref","unstructured":"6 Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma. 2008; 49: 2099-2107.","DOI":"10.1080\/10428190802455867"},{"key":"8","doi-asserted-by":"crossref","unstructured":"7 Iriyama N, Takahashi H, Hatta Y <i>et al.<\/i> Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas. Oncol Rep. 2013; 29: 805-811.","DOI":"10.3892\/or.2012.2143"},{"key":"9","doi-asserted-by":"crossref","unstructured":"8 Yamada K, Shirakawa S, Ohno R <i>et al.<\/i> A phase II study of (2&quot;R)-4\u2032-0-tetrahydropyranyladriamycin (THP) in hematological malignancies. Invest New Drugs. 1987; 5: 299-305.","DOI":"10.1007\/BF00175302"},{"key":"10","unstructured":"9 Zheng S, Zhou S, Qiao G <i>et al.<\/i> Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma. Am J Cancer Res. 2014; 5: 411-422."},{"key":"11","doi-asserted-by":"crossref","unstructured":"10 Kunimoto S, Miura K, Umezawa K <i>et al.<\/i> Cellular uptake and efflux and cytostatic activity of 4\u2032-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines. J Antibiot (Tokyo). 1984; 37: 1697-1702.","DOI":"10.7164\/antibiotics.37.1697"},{"key":"12","doi-asserted-by":"crossref","unstructured":"11 Jillella AP, Murren JR, Hamid KK <i>et al.<\/i> P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. Cancer Invest. 2000; 18: 609-613.","DOI":"10.3109\/07357900009032827"},{"key":"13","doi-asserted-by":"crossref","unstructured":"12 Kubota T, Furukawa T, Tanino H <i>et al.<\/i> Resistant mechanisms of anthracyclines--pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues. Breast Cancer. 2001; 8: 333-338.","DOI":"10.1007\/BF02967534"},{"key":"14","doi-asserted-by":"crossref","unstructured":"13 Takamatsu Y, Suzumiya J, Utsunomiya A <i>et al.<\/i> THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia\/lymphoma: a multicenter phase II study. Eur J Haematol. 2010; 84: 391-397.","DOI":"10.1111\/j.1600-0609.2010.01411.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"14 Tomita N, Kodama F, Tsuyama N <i>et al.<\/i> Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients. Hematol Oncol. 2015; 33: 9-14.","DOI":"10.1002\/hon.2136"},{"key":"16","doi-asserted-by":"crossref","unstructured":"15 Takahashi H, Miura K, Nakagawa M <i>et al.<\/i> Pirarubicin-based intensive chemotherapy followed by consolidative high-dose chemotherapies for peripheral T-cell lymphomas: A noncomparative phase 2 study. Hematol Oncol. 2022; 40: 1094-1096.","DOI":"10.1002\/hon.3043"},{"key":"17","doi-asserted-by":"crossref","unstructured":"16 Cheson BD, Horning SJ, Coiffier B <i>et al.<\/i> Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"18","doi-asserted-by":"crossref","unstructured":"17 Cheson BD, Pfistner B, Juweid ME <i>et al.<\/i> Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"19","doi-asserted-by":"crossref","unstructured":"18 Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"20","doi-asserted-by":"crossref","unstructured":"19 Shibata Y, Hara T, Kasahara S <i>et al.<\/i> CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin. Hematol Oncol. 2017; 35: 163-171.","DOI":"10.1002\/hon.2262"},{"key":"21","doi-asserted-by":"crossref","unstructured":"20 Kida S, Fuji S, Morishima T <i>et al.<\/i> Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry. Int J Hematol. 2021; 114: 246-251.","DOI":"10.1007\/s12185-021-03150-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"21 Kostakoglu L, Leonard JP, Kuji I <i>et al.<\/i> Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 2002; 94: 879-888.","DOI":"10.1002\/cncr.10336"},{"key":"23","doi-asserted-by":"crossref","unstructured":"22 Kostakoglu L, Goldsmith SJ. Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography. Clin Lymphoma. 2000; 1: 67-74.","DOI":"10.3816\/CLM.2000.n.007"},{"key":"24","unstructured":"23 Tone H, Shirai M, Danks AP <i>et al.<\/i> Toxicological studies on (2&quot;R)-4\u2032-O-tetrahydropyranyladriamycin, a new antitumor antibiotic. Subacute toxicity study in rats. Jpn J Antibiot. 1986; 39: 327-350."},{"key":"25","doi-asserted-by":"crossref","unstructured":"24 Hara T, Yoshikawa T, Goto H <i>et al.<\/i> R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial. Hematol Oncol. 2018; 36: 638-644.","DOI":"10.1002\/hon.2524"},{"key":"26","doi-asserted-by":"crossref","unstructured":"25 Mori M, Kitamura K, Masuda M <i>et al.<\/i> Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin\u2019s lymphoma. Int J Hematol. 2005; 81: 246-254.","DOI":"10.1532\/IJH97.03147"},{"key":"27","doi-asserted-by":"crossref","unstructured":"26 Itoh K, Ohtsu T, Fukuda H <i>et al.<\/i> Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin\u2019s lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol. 2002; 13: 1347-1355.","DOI":"10.1093\/annonc\/mdf287"},{"key":"28","doi-asserted-by":"crossref","unstructured":"27 Ohmachi K, Tobinai K, Kobayashi Y <i>et al.<\/i> Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin\u2019s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol. 2011; 22: 1382-1391.","DOI":"10.1093\/annonc\/mdq619"},{"key":"29","doi-asserted-by":"crossref","unstructured":"28 Terada Y, Nakamae H, Aimoto R <i>et al.<\/i> Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res. 2009; 28: 116.","DOI":"10.1186\/1756-9966-28-116"},{"key":"30","doi-asserted-by":"crossref","unstructured":"29 Hiroi T, Hosoi H, Kuriyama K <i>et al.<\/i> An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study. J Geriatr Oncol. 2023; 14: 101396.","DOI":"10.1016\/j.jgo.2022.10.011"},{"key":"31","doi-asserted-by":"crossref","unstructured":"30 Miura K, Takahashi H, Nakagawa M <i>et al.<\/i> Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma. Expert Rev Anticancer Ther. 2022; 22: 583-595.","DOI":"10.1080\/14737140.2022.2071262"},{"key":"32","doi-asserted-by":"crossref","unstructured":"31 Sibon D. Peripheral T-Cell Lymphomas: Therapeutic Approaches. Cancers (Basel). 2022; 14: 2332.","DOI":"10.3390\/cancers14092332"},{"key":"33","doi-asserted-by":"crossref","unstructured":"32 Chang EWY, Tan YH, Chan JY. Novel clinical risk stratification and treatment strategies in relapsed\/refractory peripheral T-cell lymphoma. J Hematol Oncol. 2024; 17: 38.","DOI":"10.1186\/s13045-024-01560-7"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25010\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:45:44Z","timestamp":1751085944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25010\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25010","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25010"}}